ArticlePest management science2026
Piperidine-functionalized formononetin derivatives: Design, synthesis and evaluation of antibacterial activity, modes and phenotypes.
Article in Pest management science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPlant pathogenic bacteria severely impact crop yield and quality. Long-term use of conventional bactericides has led to resistance, and raised environmental and food safety concerns, necessitating new, efficient and eco-friendly agents.
resultsThis study designed and synthesized a series of novel piperidine-functionalized formononetin derivatives (N1-N42) and evaluated their antibacterial activity. In vitro assays showed that several compounds strongly inhibited Xanthomonas oryzae pv. oryzae (Xoo) and Xanthomonas axonopodis pv. citri (Xac). Notably, thiourea-piperidine N30 and piperidine hydrochloride N42 were highly effective against Xoo, with median effective concentration (EC
conclusionN30 and N42 have good potential to be developed as formononetin-based antibacterial agents. © 2026 Society of Chemical Industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.